CClinicalTrials.gg
CompletedNCT05050331Updated Sep 19, 2024

Comparative Effectiveness of Muscle Energy Technique and Trigger Point Release in Plantar Fasciitis

An interventional study of Muscle Energy Technique and Trigger Point Release in Plantar Fasciitis, sponsored by University of Faisalabad. Completed at 1 site in Pakistan. Open to participants aged 25 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by University of Faisalabad · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
25 Years to 45 Years
Sex
All
01

Study summary

This study aimed to investigate the comparative efficacy of Muscle Energy Technique (MET) and Trigger Point Release in the treatment of Plantar Fasciitis. A single-blinded, randomized clinical trial was conducted, wherein thirty participants were randomly assigned to two parallel groups. One group received MET, while the other received Trigger Point Release, with both groups performed self-stretching exercises as part of their home program. Outcome measures included pain intensity and foot function. Treatments were administered three times a week for a duration of four weeks.

02

Conditions studied

  • Plantar Fasciitis

Keywords

  • Muscle Energy Technique
  • Trigger Point Release
03

In context

Fasciitis

235 studies on the registry are indexed under Fasciitis; 37 are open to participants now.

This study's enrollment of 30 is below the median of 54 across 192 interventional studies indexed under Fasciitis.

Browse Fasciitis studies →

Lead sponsor

University of Faisalabad is the lead sponsor of 83 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Unilateral plantar heel pain that worsens with weight-bearing activities
  • Age range: 25-45 years
  • Pain exacerbation with initial morning ambulation (i.e., walking a few steps)
  • Presence of at least one identifiable trigger point in the calf muscles

Exclusion criteria

Exclusion Criteria:

  • Bilateral heel pain
  • History of tumors in the leg or foot
  • Previous lower limb fractures
  • Recent or unresolved lower limb injuries
  • Achilles Tendinitis
  • Ankle arthritis
  • Surgery
  • Vascular Disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Muscle Energy Technique (MET) Group

    The MET protocol consisted of post-isometric relaxation applied to the gastrocnemius and soleus muscles, with 5 repetitions per set, 3 times a week, for 4 weeks

    Procedure: Muscle Energy Technique · Procedure: Self-Stretching of Calf and Plantar Fascia

  • Experimental
    Trigger Point Release Group

    The gastrocnemius muscle was subjected to trigger point release therapy, 3 sessions per week, over a period of 4 weeks

    Procedure: Trigger Point Release · Procedure: Self-Stretching of Calf and Plantar Fascia

Interventions

  • ProcedureMuscle Energy Technique

    MET involves patient-generated muscle contractions 10-20% maximum voluntary contraction from a specific position and direction, resisted by the therapist to facilitate muscle relaxation and lengthening

  • ProcedureTrigger Point Release

    Trigger point release involved applying 90 seconds of sustained thumb pressure to the trigger point, repeated three times with 30-second relaxation intervals, followed by three caudal-to-cranial longitudinal strokes along the taut band.

  • ProcedureSelf-Stretching of Calf and Plantar Fascia

    Participants performed a self-stretching program, comprising 5 repetitions of 20 seconds of stretching and 20 seconds of relaxation, twice daily

06

What researchers measure

Primary outcomes

  1. Foot Pain

    Numeric Pain Rating Scale served as the primary outcome measure, with decreasing values indicating improved patient condition and reduced pain intensity

    Time frame: Four Weeks

Secondary outcomes

  1. Foot Function

    Foot function index was utilized as a secondary outcome measure, with decreasing scores indicating improved foot function and reduced functional impairment as patient condition improves

    Time frame: Four Weeks

07

Study locations

1 site
  • The University of Faisalabad
    Faisalābad, Punjab 38000, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05050331
Lead sponsor
University of Faisalabad
Responsible party
Dr Izza Ayub; PT (Principal Investigator, University of Faisalabad) — Principal investigator
First posted
Sep 20, 2021
Start date
Jan 23, 2023
Primary completion
May 23, 2023
Completion
May 24, 2023
Last update
Sep 19, 2024

Study contacts

Dr Sidra Majeed; PT, MSPP
study director · The University of Faisalabad

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion